Glucosalino Braun

Glucosalino Braun is an intravenous solution that combines sodium chloride and glucose monohydrate in a sterile, isotonic formulation. It is supplied as a ready‑to‑use IV fluid for fluid and electrolyte replacement. The product is marketed in the European Union and is available by prescription only. It is designed to restore intravascular volume, provide essential electrolytes, and supply glucose for cellular energy during treatment and rehydration.

Glucosalino Braun is indicated for clinical situations that require rapid restoration of fluid volume and electrolyte balance. It is commonly used in hospital settings for patients who cannot tolerate oral intake. - Intravenous fluid replacement for dehydration, hemorrhage, or burns, providing isotonic saline and glucose. - Electrolyte replenishment in hyponatremia, hypochloremia, or other electrolyte disturbances. - Immediate treatment of hypoglycemia when rapid glucose delivery is required. - Peri‑operative volume expansion to maintain hemodynamic stability during surgery. - Support for patients with metabolic conditions that benefit from combined saline and glucose infusion.

Adverse reactions to Glucosalino Braun are generally related to the intravenous administration of saline and glucose solutions, and they may vary with infusion rate and patient condition.

Common: - Mild infusion site irritation or pain. - Transient hypernatremia or hyperchloremia. - Temporary increase in blood glucose levels. - Nausea or mild headache. - Mild fever or chills. - Transient hypotension during rapid infusion. - Mild electrolyte shifts causing tingling sensations. - Localized swelling at infusion site.

Serious: - Fluid overload leading to pulmonary edema. - Severe electrolyte imbalance (e.g., hypernatremia, hyperchloremia). - Anaphylactic reaction to solution components. - Severe hyperglycemia requiring insulin therapy. - Cardiac arrhythmia secondary to electrolyte disturbance. - Severe metabolic acidosis. - Renal impairment due to volume overload.

When prescribing Glucosalino Braun, clinicians should evaluate patient-specific factors to minimize risks associated with intravenous fluid therapy. - Assess fluid status and avoid administration in patients with existing fluid overload. - Monitor serum electrolytes, especially sodium and chloride, during therapy. - Check blood glucose levels before and during infusion in diabetic patients. - Use caution in patients with renal or cardiac insufficiency. - Adjust infusion rate in neonates, infants, and the elderly. - Avoid rapid bolus administration unless clinically indicated. - Ensure sterility of the solution and proper catheter care.

Glucosalino Braun may interact with other intravenous therapies or medications that affect fluid balance, electrolytes, or glucose metabolism.

Avoid: - Hypertonic saline solutions administered concurrently. - High‑dose dextrose infusions that could cause hyperglycemia. - Medications that cause rapid shifts in potassium (e.g., insulin, beta‑agonists) without electrolyte monitoring. - Concurrent administration of potassium chloride solutions, which may cause hyperkalemia.

Use with caution: - Diuretics, which may increase risk of electrolyte disturbances. - ACE inhibitors or ARBs, which can affect renal handling of sodium. - Vasopressors, requiring careful volume assessment. - Anticoagulants, due to potential catheter‑related bleeding. - Corticosteroids, as they can influence fluid retention and glucose levels.